...
首页> 外文期刊>Breast Cancer Research and Treatment >Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification
【24h】

Keratin 15, transcobalamin I and homeobox gene Hox-B13 expression in breast phyllodes tumors: novel markers in biological classification

机译:乳腺叶状肿瘤中的角蛋白15,跨钴胺素I和同源盒基因Hox-B13表达:生物学分类中的新标记

获取原文

摘要

Breast phyllodes tumors are rare neoplasms which present challenges for histological classification. Microscopic features are not always predictive of clinical behavior, and scarce data exist on the prognostic role of biological markers. Our study evaluated a series of 145 phyllodes tumors diagnosed at the Department of Pathology, Singapore General Hospital between 2006 and 2009, incorporating 91 (62.8%) benign, 40 (27.6%) borderline, and 14 (9.7%) malignant phyllodes tumors. Antibodies to keratin 15 (KRT15), transcobalamin I (TCN1), and homeobox gene Hox-B13 (HOXB13) were applied to sections cut from tissue microarray blocks. KRT15 and TCN1 positivity was defined when there was reactivity of 1% or more stromal cells, while HOXB13 positivity was defined using a H-score of 100 and above. Positive immunohistochemical expression for KRT15, TCN1, and HOXB13 was seen in 21 (14.5%), 96 (66.2%), and 66 (45.5%) of tumors, respectively. Stromal expression of KRT15, TCN1, and HOXB13 was significantly correlated with tumor grade (P < 0.001, P < 0.001, P = 0.012), stromal hypercellularity (P = 0.005, P < 0.001, P = 0.023), mitotic activity (P < 0.001), and microscopic borders (P = 0.006, P < 0.001, P = 0.011). Co-expression of TCN1 and HOXB13 was seen in 21 of 91 (23.1%) benign, 18 of 40 (45.0%) borderline, and 11 of 14 (78.6%) malignant tumors, suggesting that the dual-marker panels of TCN1 and HOXB13 might be helpful in classifying borderline and malignant tumors. Although expression of TCN1 alone was present in all malignant and 34 of 40 (85.0%) borderline tumors, a combined panel with HOXB13 excluded some benign cases and was a better discriminant for a significant proportion of borderline and malignant tumors.
机译:乳腺叶状肿瘤是罕见的肿瘤,对组织学分类提出了挑战。微观特征并不总是能够预测临床行为,并且关于生物学标志物的预后作用的数据很少。我们的研究评估了2006年至2009年间在新加坡总医院病理科诊断的一系列145例叶状肿瘤,纳入了91例(62.8%)良性,40例(27.6%)交界性和14例(9.7%)恶性的叶状肿瘤。将角蛋白15(KRT15),反钴胺素I(TCN1)和同源盒基因Hox-B13(HOXB13)的抗体应用于从组织微阵列模块上切下的切片。当基质细胞的反应性为1%或更多时,定义KRT15和TCN1阳性,而H评分为100以上,则定义HOXB13阳性。在21(14.5%),96(66.2%)和66(45.5%)的肿瘤中分别观察到KRT15,TCN1和HOXB13的阳性免疫组织化学表达。 KRT15,TCN1和HOXB13的基质表达与肿瘤级别(P <0.001,P <0.001,P = 0.012),基质细胞过多(P = 0.005,P <0.001,P = 0.023),有丝分裂活性(P < 0.001)和微观边界(P = 0.006,P <0.001,P = 0.011)。 TCN1和HOXB13的共表达在91例良性肿瘤中占21(23.1%),在40例交界性肿瘤中占18(45.0%),在14例恶性肿瘤中占11个(78.6%),这表明TCN1和HOXB13的双重标记可能有助于对边缘性和恶性肿瘤进行分类。尽管TCN1表达单独存在于所有恶性肿瘤和40例边缘性肿瘤中的34例(85.0%)中,但结合HOXB13的小组排除了一些良性病例,并且对大部分边缘性和恶性肿瘤有更好的判别。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号